Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Cyclically Adjusted Revenue per Share: ¥0.54 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600381 Qinghai Spring Medicinal Resources Technology Co Ltd SHSE:600381
59 GF Score
Price ¥4.15
GF Value ¥5.89
Valuation Significantly Undervalued
View Full Analysis

What is Qinghai Spring Medicinal Resources Technology Co Cyclically Adjusted Revenue per Share?

Qinghai Spring Medicinal Resources Technology Co SHSE:600381 +2.47% 59 Cyclically Adjusted Revenue per Share is ¥0.54 as of Mar. 2026. GuruFocus rates SHSE:600381 with a GF Score™ of 59/100 and a GF Value™ of ¥5.89 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Qinghai Spring Medicinal Resources Technology Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥0.079. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥0.54 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Qinghai Spring Medicinal Resources Technology Co's average Cyclically Adjusted Revenue Growth Rate was -20.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -23.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -18.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Qinghai Spring Medicinal Resources Technology Co was 4.80% per year. The lowest was -23.30% per year. And the median was -7.60% per year.

As of today (2026-08-05), Qinghai Spring Medicinal Resources Technology Co's current stock price is ¥4.15. Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥0.54. Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted PS Ratio of today is 7.69.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Qinghai Spring Medicinal Resources Technology Co was 13.13. The lowest was 1.86. And the median was 6.00.


Qinghai Spring Medicinal Resources Technology Co  (SHSE:600381) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.15/0.54
=7.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Qinghai Spring Medicinal Resources Technology Co was 13.13. The lowest was 1.86. And the median was 6.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Qinghai Spring Medicinal Resources Technology Co Cyclically Adjusted Revenue per Share Related Terms


Qinghai Spring Medicinal Resources Technology Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qinghai Spring Medicinal Resources Technology Co Cyclically Adjusted Revenue per Share Chart

Qinghai Spring Medicinal Resources Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.41 1.22 1.19 0.75 0.55

Qinghai Spring Medicinal Resources Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.65 0.59 0.55 0.54

SHSE:600381 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qinghai Spring Medicinal Resources Technology Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600381
59GF Score
Qinghai Spring Medicinal Resources Technology Co Ltd SHSE:600381
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qinghai Spring Medicinal Resources Technology Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Qinghai Spring Medicinal Resources Technology Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.079/116.3033*116.3033
=0.079

Current CPI (Mar. 2026) = 116.3033.

Qinghai Spring Medicinal Resources Technology Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.195 101.400 0.224
201609 0.250 102.400 0.284
201612 0.626 102.600 0.710
201703 0.174 103.200 0.196
201706 0.145 103.100 0.164
201709 0.222 104.100 0.248
201712 0.179 104.500 0.199
201803 0.158 105.300 0.175
201806 0.141 104.900 0.156
201809 0.105 106.600 0.115
201812 0.189 106.500 0.206
201903 0.123 107.700 0.133
201906 0.116 107.700 0.125
201909 0.061 109.800 0.065
201912 0.119 111.200 0.124
202003 0.022 112.300 0.023
202006 0.036 110.400 0.038
202009 0.049 111.700 0.051
202012 0.102 111.500 0.106
202103 0.034 112.662 0.035
202106 0.046 111.769 0.048
202109 0.058 112.215 0.060
202112 0.077 113.108 0.079
202203 0.128 114.335 0.130
202206 0.051 114.558 0.052
202209 0.040 115.339 0.040
202212 0.054 115.116 0.055
202303 0.096 115.116 0.097
202306 0.087 114.558 0.088
202309 0.092 115.339 0.093
202312 0.093 114.781 0.094
202403 0.144 115.227 0.145
202406 0.092 114.781 0.093
202409 0.103 115.785 0.103
202412 0.123 114.893 0.125
202503 0.146 115.116 0.148
202506 0.055 114.907 0.056
202509 0.155 115.471 0.156
202512 0.302 115.832 0.303
202603 0.079 116.303 0.079

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥0.54 mean?
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) has a Cyclically Adjusted Revenue per Share of ¥0.54 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors.
Is Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted Revenue per Share too high?
Qinghai Spring Medicinal Resources Technology Co's current Cyclically Adjusted Revenue per Share is ¥0.54. Overall, Qinghai Spring Medicinal Resources Technology Co has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Qinghai Spring Medicinal Resources Technology Co's Cyclically Adjusted Revenue per Share of ¥0.54 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. Qinghai Spring Medicinal Resources Technology Co's current Cyclically Adjusted Revenue per Share is ¥0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qinghai Spring Medicinal Resources Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥5.89, compared to a current price of ¥4.15 — trading 29.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥0.54. Qinghai Spring Medicinal Resources Technology Co's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Qinghai Spring Medicinal Resources Technology Co (SHSE:600381), the current Cyclically Adjusted Revenue per Share is ¥0.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Overvalued in 2026?

Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co stock appears to be undervalued. The current stock price of ¥4.15 is trading 29.5% below its estimated GF Value™ of ¥5.89. GuruFocus considers Qinghai Spring Medicinal Resources Technology Co to be Significantly Undervalued.

Key valuation signals for SHSE:600381:

  • Cyclically Adjusted Revenue per Share: ¥0.54
  • GF Value™: ¥5.89 vs. price of ¥4.15 (29.5% below fair value)
  • GF Score™: 59/100

No single metric tells the full story. See the SHSE:600381 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Qinghai Spring Medicinal Resources Technology Co Business Description

Address East New Road 1, Xining Economic and Technological Development Zone, Xining, CHN, 810007
Qinghai Spring Medicinal Resources Technology Co Ltd is a China-based company that principally engaged in the integrated development, utilization, production, sales, and consulting services of the natural advantageous resources on the Qinghai-Tibet plateau, as well as the development and utilization of other biological resources. The Company's main products are the cordyceps sinensis series products under the Verygrass brand, which includes cordyceps sinensis pure powder tablet, processed cordyceps sinensis, and raw cordyceps sinensis.
59GF Score

Get the complete analysis for SHSE:600381

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.15
Price
¥5.89
GF Value